mevalonic acid and Immunologic Deficiency Syndromes

mevalonic acid has been researched along with Immunologic Deficiency Syndromes in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bonneville, M; Catros, V; Léger, A; Robard, M; Santolaria, T; Scotet, E	1

Other Studies

1 other study(ies) available for mevalonic acid and Immunologic Deficiency Syndromes

Article	Year
Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo. Journal of immunology (Baltimore, Md. : 1950), 2013, Aug-15, Volume: 191, Issue:4 Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Diphosphonates; Drug Administration Schedule; Humans; Immunologic Deficiency Syndromes; Immunotherapy, Adoptive; Lymphocyte Activation; Male; Mevalonic Acid; Mice; Mice, Mutant Strains; Mice, SCID; Pamidronate; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Xenograft Model Antitumor Assays	2013

Article

Year

Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.

Journal of immunology (Baltimore, Md. : 1950), 2013, Aug-15, Volume: 191, Issue:4

Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Diphosphonates; Drug Administration Schedule; Humans; Immunologic Deficiency Syndromes; Immunotherapy, Adoptive; Lymphocyte Activation; Male; Mevalonic Acid; Mice; Mice, Mutant Strains; Mice, SCID; Pamidronate; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Xenograft Model Antitumor Assays

2013